Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 2NET 1CNS 1

Conditions

Brain Neoplasms 362Glioblastoma 299Glioma 239Neuroblastoma 95Neoplasms 70Central Nervous System Neoplasms 62Astrocytoma 61Meningioma 59Breast Neoplasms 51Lung Neoplasms 46Carcinoma, Non-Small-Cell Lung 46Melanoma 40Sarcoma 35Medulloblastoma 33Meningeal Carcinomatosis 32Recurrence 31Neoplasm Metastasis 28Diffuse Intrinsic Pontine Glioma 28Prostatic Neoplasms 27Pheochromocytoma 26Paraganglioma 26Neurofibromatosis 1 26Pancreatic Neoplasms 24Ovarian Neoplasms 24Oligodendroglioma 22Ependymoma 21Osteosarcoma 20Head and Neck Neoplasms 20Spinal Cord Neoplasms 19Kidney Neoplasms 19

Interventions

fluorodopa F 18 1Furosemide 14-chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Congenital Hyperinsulinism × CNS × Clear all
NCT04706910 2026-02-09

18F-DOPA II - PET Imaging Optimization

University of Alberta

Phase 3 Recruiting
800 enrolled
CNSEndocrineNET

Brain Neoplasms, Neuroblastoma, Parkinson Disease, Neuroendocrine Tumors, Lewy Body Disease, Congenital Hyperinsulinism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡